Skip to main content

Table 1 Patients previously reported with goblet cell carcinoid in the rectum

From: Goblet cell carcinoid of the rectum: a case report

No.

Author

Year

Age

M/F

Coexisting component

Tumor depth

Synchronous metastasis

Treatment

Adjuvant chemotherapy

Site of recurrence

Treatment of recurrence

Prognosis (months)

1

Ishii [13]

2001

71

M

Typical carcinoid, WDA

T4b

Regional lymph node

Miles’ operation

None

Subcutaneous, testis

None

Died (9)

2

Kato [14]

2002

44

M

None

T3

None

Total colectomy (accompanied by UC)

None

Liver, brain, peritoneum

Right lobectomy of the liver, intraperitoneal administration of CDDP

Died (39)

3

Wakahara [15]

2010

58

M

Typical carcinoid

T4b

Pelvic lymph node

Total pelvic exenteration, LLND

5-FU, LV

Groin and pelvic lymph node

Lymphadenectomy

Alive (> 60)

4

Yamabuki [7]

2011

75

M

None

T2

Regional lymp node

Miles’ operation

None

Lung

FOLFOX

Alive (15)

5

Kang[16]

2016

46

F

None

T1

None

Low anterior resection

None

None

None

Alive (10)

6

Present patient

2020

77

M

Wda

T3

None

Miles’ operation

None

Liver

FOLFOX+BV, CapeOX+BV, IRIS+BV

Alive (27)

  1. WDA well-differenciated adenocarcinoma; n.d. not described; UC ulcerative colitis; LLND lateral lymph node dissection; CDDP cisplatin, 5-FU; LV fluorouracil and leucovorin; FOLFOX 5-fluorouracil, leucovorin, oxaliplatin; BV bevacizumab; CapeOX capecitabine + oxaliplatin; IRIS irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate); M male; F female